ReviewLife sciences2022
MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.
Review in Life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Neurodegenerative and Cognitive Consequences of Long COVID.International journal of molecular sciences · 2026Review
- Translational MicroRNA research in COVID-19: bridging in Silico prediction with clinical biomarker potential.Clinical and experimental medicine · 2026Article
- Identification of SnRNA U6 as an endogenous reference gene for normalization of MiRNA expression data in COVID-19 patients.Scientific reports · 2025Article
- Modulation of RAAS receptors and miRNAs in COVID-19: implications for disease severity, immune response, and potential therapeutic targets.BMC infectious diseases · 2025Observational
- Immuno-epigenetic paradigms in coronavirus infection.Frontiers in immunology · 2025Review
- Human cytomegalovirus microRNAs: strategies for immune evasion and viral latency.Archives of virology · 2024Review
- Cross Talk between MicroRNAs and Dengue Virus.The American journal of tropical medicine and hygiene · 2024Review
- A comprehensive SARS-CoV-2 and COVID-19 review, Part 2: host extracellular to systemic effects of SARS-CoV-2 infection.European journal of human genetics : EJHG · 2024Review
- MicroRNA analysis of medium/large placenta extracellular vesicles in normal and preeclampsia pregnancies.Frontiers in cardiovascular medicine · 2024Article
- Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics.Molecular diversity · 2023Article
- Effect of the SARS-CoV-2 Delta-associated G15U mutation on the s2m element dimerization and its interactions with miR-1307-3p.RNA (New York, N.Y.) · 2023Article
- MicroRNAs: Small but Key Players in Viral Infections and Immune Responses to Viral Pathogens.Biology · 2023Review
- Evaluation of miRNA-16-2-3P, miRNA-618 levels and their diagnostic and prognostic value in the regulation of immune response during SARS Cov-2 infection.Immunogenetics · 2023Article
- Salivary miRNA Profiles in COVID-19 Patients with Different Disease Severities.International journal of molecular sciences · 2023Article
- Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients.Archives of virology · 2023Article
- Isothermal exponential amplification reactions triggered by circular templates (cEXPAR) targeting miRNA.Molecular biology reports · 2023Article
- miRNAs as a Potential Biomarker in the COVID-19 Infection and Complications Course, Severity, and Outcome.Diagnostics (Basel, Switzerland) · 2023Review
- The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection.Frontiers in cell and developmental biology · 2023Review
- Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature.Frontiers in molecular neuroscience · 2023Article
- Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection.Structural chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a highly transmissible disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), affects 226 countries and continents, and has resulted in >6.2 million deaths worldwide. Despite the efforts of all scientific institutions worldwide to identify potential therapeutics, no specific drug has been approved by the FDA to treat the COVID-19 patient. SARS-CoV-2 variants of concerns make the potential of publicly known therapeutics to respond to and detect disease onset highly improbable. The quest for universal therapeutics pointed to the ability of RNA-based molecules to shield and detect the adverse effects of the COVID-19 illness. One such candidate, miRNA (microRNA), works on regulating the differential expression of the target gene post-transcriptionally. The prime focus of this review is to report the critical miRNA molecule and their regular expression in patients with COVID-19 infection and associated comorbidities. Viral and host miRNAs control the etiology of COVID-19 infection throughout the life cycle and host inflammatory response, where host miRNAs are identified as a double-edged showing as a proviral and antiviral response. The review also covered the role of viral miRNAs in mediating host cell signaling expression during disease pathology. Studying molecular interactions between the host and the SARS-CoV-2 virus during COVID-19 pathogenesis offers the chance to use miRNA-based therapeutics to reduce the severity of the illness. By utilizing an appropriate delivery vehicle, these small non-coding RNA could be envisioned as a promising biomarker in designing a practical RNAi-based treatment approach of clinical significance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.